Kymera Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
188
- Stock Symbol
-
KYMR
- Share Price
-
$27.16
- (As of Monday Closing)
Kymera Therapeutics General Information
Description
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Contact Information
Website
www.kymeratx.comCorporate Office
- 500 North Beacon Street
- 4th Floor
- Watertown, MA 02472
- United States
Corporate Office
- 500 North Beacon Street
- 4th Floor
- Watertown, MA 02472
- United States
Kymera Therapeutics Stock Performance
As of 21-Apr-2025, Kymera Therapeutics’s stock price is $27.16. Its current market cap is $1.76B with 64.9M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $27.16 | $25.97 | $19.45 - $53.27 | $1.76B | 64.9M | 679K | -$2.98 |
Kymera Therapeutics Financials Summary
As of 31-Dec-2024, Kymera Therapeutics has a trailing 12-month revenue of $47.1M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 2,143,768 | 2,143,768 | 1,135,727 | 904,256 |
| Revenue | 47,072 | 47,072 | 78,592 | 46,826 |
| EBITDA | (252,811) | (252,811) | (160,430) | (157,056) |
| Net Income | (223,858) | (223,858) | (146,962) | (154,808) |
| Total Assets | 978,035 | 978,035 | 575,759 | 603,134 |
| Total Debt | 87,761 | 87,761 | 84,674 | 17,335 |
Kymera Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kymera Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Kymera Therapeutics Comparisons
Industry
Financing
Details
Kymera Therapeutics Competitors (36)
One of Kymera Therapeutics’s 36 competitors is Foghorn Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foghorn Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Cullgen | Venture Capital-Backed | San Diego, CA | ||||
| Vividion Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Sitryx | Venture Capital-Backed | Oxford, United Kingdom |
Kymera Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kymera Therapeutics Patents
Kymera Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250059164-A1 | Irak degraders and uses thereof | Pending | 23-Jun-2023 | ||
| US-20240252656-A1 | Salt forms of irak4 degraders | Pending | 13-Oct-2022 | ||
| US-20240174665-A1 | Cdk2 inhibitors and uses thereof | Pending | 19-Aug-2022 | ||
| US-20240173419-A1 | Cdk2 degraders and uses thereof | Pending | 19-Aug-2022 | ||
| EP-4522154-A1 | Bcl-xl/bcl-2 degraders and uses thereof | Pending | 12-May-2022 | A61K45/06 |
Kymera Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kymera Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
36.38 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Kymera Therapeutics FAQs
-
When was Kymera Therapeutics founded?
Kymera Therapeutics was founded in 2015.
-
Where is Kymera Therapeutics headquartered?
Kymera Therapeutics is headquartered in Watertown, MA.
-
What is the size of Kymera Therapeutics?
Kymera Therapeutics has 188 total employees.
-
What industry is Kymera Therapeutics in?
Kymera Therapeutics’s primary industry is Biotechnology.
-
Is Kymera Therapeutics a private or public company?
Kymera Therapeutics is a Public company.
-
What is Kymera Therapeutics’s stock symbol?
The ticker symbol for Kymera Therapeutics is KYMR.
-
What is the current stock price of Kymera Therapeutics?
As of 21-Apr-2025 the stock price of Kymera Therapeutics is $27.16.
-
What is the current market cap of Kymera Therapeutics?
The current market capitalization of Kymera Therapeutics is $1.76B.
-
What is Kymera Therapeutics’s current revenue?
The trailing twelve month revenue for Kymera Therapeutics is $47.1M.
-
Who are Kymera Therapeutics’s competitors?
Foghorn Therapeutics, Nurix Therapeutics, Cullgen, Vividion Therapeutics, and Sitryx are some of the 36 competitors of Kymera Therapeutics.
-
What is Kymera Therapeutics’s annual earnings per share (EPS)?
Kymera Therapeutics’s EPS for 12 months was -$2.98.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
